Algeta

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway.